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Session: 244. HIV and HBV
Background. Patients coinfected with HIV and HBV are at higher risk of developing chronic HBV infection, cirrhosis and hepatocellular carcinoma. In Mozambique, where the HIV prevalence is among the highest in the world, the epidemiology of HBV and the profile of HBV resistance to 3TC in HIV-infected patients is barely known.
Methods. A cross-sectional study was conducted between May and November 2012 at two health centers in Maputo, Mozambique, to consecutively enroll ART-naïve HIV-infected adults (AN-HIV). All participants were tested for hepatitis B surface antigen (HBsAg). CD4 + T cells count and plasma HBV DNA, HBV genotyping and profile of HBV resistance mutations to 3TC were measured in all coinfected patients.
Results. A total of 518 AN-HIV were enrolled. The median age was 33 years old and 66.8% were women. The median CD4 + T cells count was 361 cells/mm 3 and 47 (9.1%) were coinfected with HBV (HBsAg + ). Out of 46 coinfected patients, 24 (55.2%) had HBV DNA ≥ 20 -< 20 000 and 12 (26.1%) had HBV-DNA ≥20 000. APRI > 2.0 was reported in 4.3% of coinfected and FIB4 > 3.25 was reported in 4.4%. ALT and AST were within normal ranges in all HBsAg + patients. Genotype A was identified in 25/27 (92.6%) and genotype E in 2/27 (7.4%) of patients. No patient had 3TC-resistance mutation.
Conclusion. Data from this study showed that HBV infection was prevalent among ART naïve HIV infected adults in Mozambique. The most frequent genotype of HBV was genotype A and no 3TC-resistance was detected. Overall, our data suggests that integration of screening of HBV into HIV care and treatment activities is needed to improve the health conditions of HIV/HBV coinfected patients. Background. Historically, eradication of HCV with interferon-based treatments was linked with decreased incidence of diabetes. While viral clearance with direct acting agents (DAAs) may be associated with acute decreases in fasting glucose levels and hemoglobin A1c (HbA1c), there remains a need for larger prospective studies to address the longterm impact of sustained viral response (SVR) achieved with DAAs on glucose metabolism.
Methods. Prospective longitudinal cohort study of 251 subjects with chronic HCV (100% genotype 1a/b, 31% HIV+, 17% diabetes) evaluated pre-and post-DAA therapy with median follow-up of 28 mos. Change in HbA1c, glucose, lipid and transaminase levels were compared based on SVR, HIV, diabetes status and fibrosis stage.
Results. There was no difference in change in HbA1c between subjects who achieved SVR (n = 241) compared with those who did not. Mean change in HbA1c did not differ from zero (−0.022 ± 0.53%) for those with SVR. Further, when subjects were grouped based on HIV, diabetes or fibrosis stage, there were no significant differences in changes in HbA1c or glucose following SVR. Subjects with HIV had smaller reductions in transaminase values (change ALT −33.3 ± 51 IU/L HIV+ vs. −47.8 ± 45 IU/L HIV-, P = 0.0007). Following SVR, total and LDL cholesterol increased (P = 0.0002 and P = 0.0003, respectively) whereas triglyceride levels decreased (P = 0.008). A greater proportion of subjects (7%) started or increased medication therapy for diabetes following SVR compared with the percentage who decreased diabetes therapy (3%). There was a statistically significant positive correlation between change in BMI and change in HbA1c (r=0.17, P = 0.006).
Conclusion. The current study failed to identify sustained benefits in glucose or HbA1c in HCV treated patients, irrespective of HIV, diabetes or fibrosis stage. HIV infection blunted improvements in transaminase levels related to SVR. While HbA1c
